Integral Health Asset Management LLC Boosts Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Integral Health Asset Management LLC raised its position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 36.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375,000 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Scholar Rock makes up 1.4% of Integral Health Asset Management LLC’s portfolio, making the stock its 25th biggest position. Integral Health Asset Management LLC owned about 0.40% of Scholar Rock worth $16,208,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SRRK. Barclays PLC grew its position in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock valued at $1,324,000 after acquiring an additional 84,118 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Scholar Rock by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after purchasing an additional 379 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after purchasing an additional 269 shares in the last quarter. Hamilton Lane Advisors LLC acquired a new position in shares of Scholar Rock during the fourth quarter worth about $1,274,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after purchasing an additional 1,031 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Buying and Selling

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the sale, the insider now owns 111,084 shares in the company, valued at $4,154,541.60. This represents a 38.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Tracey Sacco sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the sale, the insider now owns 71,750 shares in the company, valued at $2,355,552.50. The trade was a 6.51% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 255,231 shares of company stock worth $9,220,236. 13.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $42.67.

Scholar Rock Trading Down 0.5%

NASDAQ:SRRK opened at $30.85 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The business’s 50-day simple moving average is $31.63 and its 200 day simple moving average is $35.92. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -13.13 and a beta of 0.37.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.